Investor Omega Fund IV, L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Omega Fund IV, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2024-11-14 13G/A REPL / Replimune Group, Inc. 3,249,991 2,709,991
2024-02-14 13G/A REPL / Replimune Group, Inc. 3,610,478 3,249,991
2023-02-13 13G/A REPL / Replimune Group, Inc. 5,055,552 3,610,478
2022-02-14 13G/A REPL / Replimune Group, Inc. 5,329,783 5,055,552
2021-02-12 13G/A EPIX / ESSA Pharma Inc. 1,782,151 777,996
2020-08-06 13G ALPN / Alpine Immune Sciences, Inc. 1,670,370
2020-02-14 13G/A EPIX / ESSA Pharma Inc. 1,086,098 1,782,151
2020-02-14 13G/A REPL / Replimune Group, Inc. 5,103,455 5,329,783
2020-02-14 13G/A TBIO / Telesis Bio, Inc. 2,437,603
2019-02-13 13D EPIX / ESSA Pharma Inc. 22,303,029 1,086,098
2019-02-13 13G REPL / Replimune Group, Inc. 5,103,455
2018-02-09 13G/A EPIX / ESSA Pharma Inc. 2,606,059 22,303,029
2017-02-14 13G/A ZCOR / Zyla Life Sciences 2,500,354 2,575,352
2016-02-10 13G/A ZCOR / Zyla Life Sciences 2,500,354
2016-01-22 13G EPIX / ESSA Pharma Inc. 2,606,059
2015-02-13 13G ZCOR / Zyla Life Sciences 3,308,558